BOSTON, Jan. 23, 2013 /PRNewswire/ -- CBI is pleased to announce the addition of Maame Ewusi-Mensah Frimpong to its esteemed lineup of keynote addresses at PCC 2013, taking place January 29-30 at the Ritz-Carlton in Washington, DC. Ms. Frimpong currently serves as the Deputy Assistant Attorney General, Consumer Protection Branch, Civil Division at TheUnited States Department of Justice. As one of the individuals in charge of overseeing the Justice Department’s Food, Drug, and Cosmetic Act cases, she will address the crowd of more than 400 legal and compliance professionals to discuss DOJ’s 2013 areas of high priority, including increased attention and enforcement related to drug safety and GMP matters. She will then join a panel discussion with other government notables including U.S. Attorney Timothy Heaphy, U.S. Attorney John F. Walsh, U.S. Attorney Carmen M. Ortiz, Assistant U.S. Attorney Margaret L. Hutchinson and FDA Deputy Chief Counsel Rick Blumberg.
Frimpong was appointed the Deputy Assistant Attorney General of the Consumer Protection Branch of the Civil Division in July 2012 by Attorney General Eric H. Holder, Jr. She had been acting in that role since March 2011 when she was named Acting Deputy Assistant Attorney General of the newly-reorganized Branch. As the DAAG, Ms. Frimpong sets the strategic direction of the Branch and implements its expanded consumer protection footprint, leading the transition of the Branch to its expanded mission and new leadership. She has deepened the Consumer Protection Branch’s relationships with its agency partners and consumer advocacy partners, spearheaded a number of new initiatives and launched several new investigations in new areas of consumer protection.
For the last decade, CBI’s Compliance Congress has served as the reigning senior-level meeting place for the life science industry’s legal, compliance and regulatory executives tasked with implementing and maintaining compliance initiatives organization-wide. PCC’s comprehensive agenda boasts more than 10 dynamic keynotes, 50 educational and networking opportunities, and, in addition to Ms. Frimpong, 95 distinguished faculty members including industry representation from Auxilium, Biogen Idec, Boehringer Ingelheim, Celgene, Covidien Pharmaceuticals, Dendreon, Eisai, Endo, Fresenius, Incyte, Ipsen, Johnson & Johnson, Lundbeck, Meda, Medicis, Novartis Pharmaceuticals Corporation, Purdue, Par, Pfizer, Sigma-Tau, Sunovion, Takeda, Teva and UCB, as well as government perspectives from the DOJ, SEC and FDA.
Congress attendees are afforded the exclusive opportunity to customize their Congress experience by choosing various breakout sessions, interactive workshops and concurrent tracks surrounding all aspects of corporate compliance, including Sunshine and Global HCP Aggregate Spend Reporting, Promotional Compliance and Off-Label Controls, Clinical Research and Pre-Approval Communications, Global ABAC and International Compliance, Effective Training and Monitoring, Conducting Investigations, CIA Readiness, Government Pricing and much more.
CBI’s Compliance Congress is the pharmaceutical industry’s premier meeting place for cutting-edge content, valuable networking and unparalleled programming. For more information on the conference or to download the brochure, please visit www.cbinet.com/pcc.
About CBI:
CBI, an Advanstar company, is the leading provider of market-driven, unbiased conferences for the pharmaceutical, biotechnology, medical device and healthcare industries. CBI offers specialized information presented in interactive formats by thought leaders and regulators. For more information, please visit www.cbinet.com; for media inquiries, contact Emily Forest, Senior Marketing Manager at emily.forest@cbinet.com.
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.
SOURCE CBI
